SEP 1 3 ZODA 29



## Patent Application Attorney Docket No.PC25623A

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this / S day of September 2004.

By

(Signature of person mailing)
Kelley D. Surprenant

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bruce M. Bechle, et al. :

APPLICATION NO.: 10/807,838 : Examiner: To be assigned

FILING DATE: March 23, 2004 : Group Art Unit: 1614

TITLE: Quinoline and Quinoxaline Compounds :

Commissioner for Patents
P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

## Patent Application Attorney Docket No.PC25623A

This information disclosure statement is being submitted prior to receiving a first office action; therefore, no fee is required. In the event that an office action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

Date:

Respectfully submitted,

Lisa A. Samuels

Attorney for Applicant(s)

Reg. No. 43,080

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 686-0349



INFOR	<del>&gt;</del>	ON DR	ELOSI	URE CIT	ATION	AT	ry. DOC	KET NO	D. PC2562	23A	SERIAL NO	. 10/80	7,838	}
INFORMATION DESCLOSURE CITATION (Use several sheets if necessary)							APPLICANT Mary T. Didiuk, et al.							
,									h 23, 200	GROUP 1614				
									JMENTS			·		
XAMINER INITIAL		DOCUMENT NUMBER								NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIA	
									<u>-</u> .				-	
									-					
	<u> </u>									-				
					F	OREI	GN PAT	ENT DO	CUMEN	rs		•		
	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	
			<b>,</b> -					r -					YES	N
	DE	3	5	1	4	6	4		4/7/22	Germany	12	1		
	wo	9	6	1	9	4	5	8	6/27/96	Internation	International C07D			
	wo	0	1	4	0	1	9	0	6/7/01	Internation	al A61K	31/47		
-														
	<u>'                                    </u>		ОТН	ER DOC	UMENT	S (Inc	luding A	uthor, T	itle, Date,	Pertinent Pa	ges, Etc.)			•
		Edwar	rdo I D	et al. Ma	notomidal	Andma	on Posont	or Agonie	s Basad on	A (trifluormmeth)	/I)_2H_nyrano(3_2	-alauinolin		
		Edwards, J. P., et al., Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin -2-one, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1003-1008 (1999).												
		Massa Eur. J	acret, M., . Org. Ch	et al., <i>Pal.</i> em., pp. 1	ladium(0)- 29-134, (1	Catalyz 999).	ed Asymm	etric Synt	hesis of 1,2,	3,4-Tetrahydro-2	2-vinylquinoxaline	9s,		
										<i>quinoline-4-car</i> b pp. 2822-2827, (	oxylic Esters by (2001).	a 	·	
										8, accession # 1 hem. 1972-1992	992:490239, 2, 10, p. 1245-124	19		
		1 0.0	0110	000,01	, , , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			,			,, <u></u>		_	
XAMINE	:R							DATE C	ONSIDERE	D				
_														_
			sidered, who	ether or not ci	tation is in co	nformance	with MPEP 6	09; Draw line	through citation	if not in conformance	and not considered. It	ndude copy of th	nis form v	vith
ext commun	iication to a	applicant.												

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE